{"sample_id": "AMGN_0001193125-22-211860_2022-08-04", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2022-08-04", "acc_no": "0001193125-22-211860", "sic": "2836", "text_length": 20234}, "classification": {"clinical": "no", "summary": "Amgen announces a merger agreement with ChemoCentryx for $52 per share. The deal is subject to regulatory and stockholder approvals.", "event_type": "Initiation", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "same", "evidence_spans": "Item 1.01, Item 7.01"}}
{"sample_id": "AMGN_0001193125-21-229599_2021-07-30", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2021-07-30", "acc_no": "0001193125-21-229599", "sic": "2836", "text_length": 6069}, "classification": {"clinical": "no", "summary": "Amgen appoints S. Omar Ishrak to the Board of Directors, effective July 30, 2021.", "event_type": "Appointment", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "2021-07-29", "evidence_spans": "Item 5.02, Exhibit 99.1"}}
{"sample_id": "AMGN_0001193125-21-177693_2021-06-01", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2021-06-01", "acc_no": "0001193125-21-177693", "sic": "2836", "text_length": 6854}, "classification": {"clinical": "no", "summary": "Amgen enters collaboration agreement with Kyowa Kirin for KHK4083, an anti-OX40 monoclonal antibody, with $400 million upfront and potential $850 million in milestones.", "event_type": "Initiation", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "same", "evidence_spans": "Item 1.01, Exhibit 99.1"}}
{"sample_id": "AMGN_0001193125-22-211860_2022-08-04", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2022-08-04", "acc_no": "0001193125-22-211860", "sic": "2836", "text_length": 20234}, "classification": {"clinical": "no", "summary": "Amgen announces a merger agreement with ChemoCentryx for $52 per share. The deal is subject to regulatory and stockholder approvals.", "event_type": "Initiation", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "same", "evidence_spans": "Item 1.01, Item 7.01"}}
{"sample_id": "AMGN_0001193125-21-229599_2021-07-30", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2021-07-30", "acc_no": "0001193125-21-229599", "sic": "2836", "text_length": 6069}, "classification": {"clinical": "no", "summary": "Amgen appoints S. Omar Ishrak to the Board of Directors, effective July 30, 2021.", "event_type": "Appointment", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "2021-07-29", "evidence_spans": "Item 5.02, Exhibit 99.1"}}
{"sample_id": "AMGN_0001193125-21-177693_2021-06-01", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2021-06-01", "acc_no": "0001193125-21-177693", "sic": "2836", "text_length": 6854}, "classification": {"clinical": "no", "summary": "Amgen enters collaboration agreement with Kyowa Kirin for KHK4083, an anti-OX40 monoclonal antibody, with $400 million upfront and potential $850 million in milestones.", "event_type": "Initiation", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "same", "evidence_spans": "Item 1.01, Exhibit 99.1"}}
{"sample_id": "AMGN_0001193125-21-068571_2021-03-04", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2021-03-04", "acc_no": "0001193125-21-068571", "sic": "2836", "text_length": 22709}, "classification": {"clinical": "no", "summary": "Amgen announces a merger agreement with Five Prime Therapeutics, including a tender offer for Five Prime's shares at $38.00 per share.", "event_type": "Modification", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "same", "evidence_spans": "Item 1.01, Item 7.01"}}
{"sample_id": "AMGN_0001193125-19-312129_2019-12-12", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2019-12-12", "acc_no": "0001193125-19-312129", "sic": "2836", "text_length": 5843}, "classification": {"clinical": "no", "summary": "Amgen entered a $2.5 billion revolving credit agreement for general corporate purposes.", "event_type": "Modification", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "unknown", "evidence_spans": "Item 1.01, Entry into a Material Definitive Agreement"}}
{"sample_id": "AMGN_0001193125-19-280582_2019-10-31", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2019-10-31", "acc_no": "0001193125-19-280582", "sic": "2836", "text_length": 17393}, "classification": {"clinical": "no", "summary": "Amgen and BeiGene enter a collaboration for oncology products in China and a $2.734 billion share purchase agreement.", "event_type": "Initiation, Modification", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "same", "evidence_spans": "Item 1.01, Exhibit 99.1"}}
{"sample_id": "AMGN_0001193125-19-228830_2019-08-26", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2019-08-26", "acc_no": "0001193125-19-228830", "sic": "2836", "text_length": 9370}, "classification": {"clinical": "no", "summary": "Amgen acquires OTEZLA from Celgene for $13.4 billion, subject to regulatory approvals and BMS-Celgene merger.", "event_type": "unknown", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "2019-08-26", "evidence_spans": "Item 7.01, Exhibit 99.1"}}
{"sample_id": "AMGN_0001193125-17-377669_2017-12-22", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2017-12-22", "acc_no": "0001193125-17-377669", "sic": "2836", "text_length": 8657}, "classification": {"clinical": "no", "summary": "Amgen discusses the expected impact of U.S. tax reform on the company's financials, including a GAAP net tax expense of $6-6.5 billion.", "event_type": "unknown", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "unknown", "evidence_spans": "Item 7.01 Regulation FD Disclosure."}}
{"sample_id": "AMGN_0001193125-13-345824_2013-08-26", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2013-08-26", "acc_no": "0001193125-13-345824", "sic": "2836", "text_length": 23673}, "classification": {"clinical": "no", "summary": "Amgen announces a merger agreement with Onyx Pharmaceuticals, including a tender offer for Onyx's shares and financing arrangements.", "event_type": "Initiation", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "2013-08-25", "evidence_spans": "Item 1.01, Item 8.01, Exhibit 99.1"}}
{"sample_id": "AMGN_0001193125-12-146130_2012-04-02", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2012-04-02", "acc_no": "0001193125-12-146130", "sic": "2836", "text_length": 4815}, "classification": {"clinical": "no", "summary": "Amgen and AstraZeneca enter into a collaboration agreement for the development, manufacture, and commercialization of five clinical stage inflammation programs.", "event_type": "Initiation", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "2012-04-02", "evidence_spans": "Item 1.01, Collaboration Agreement, press released on April 2, 2012, Exhibit 99.1"}}
{"sample_id": "AMGN_0001193125-12-024302_2012-01-26", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2012-01-26", "acc_no": "0001193125-12-024302", "sic": "2836", "text_length": 16689}, "classification": {"clinical": "no", "summary": "Amgen Inc. entered into a merger agreement with Micromet, Inc. to acquire all outstanding shares for $11.00 per share.", "event_type": "Initiation", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "same", "evidence_spans": "Item 1.01, Exhibit 99.2"}}
{"sample_id": "AMGN_0001193125-08-196495_2008-09-16", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2008-09-16", "acc_no": "0001193125-08-196495", "sic": "2836", "text_length": 4388}, "classification": {"clinical": "yes", "summary": "Denosumab reduced vertebral, hip, and nonvertebral fracture risks in a Phase 3 trial for postmenopausal osteoporosis.", "event_type": "Results", "phase": "3", "outcome": "positive", "confidence": "final", "press_release_date": "same", "evidence_spans": "Pivotal Fracture Trial, 60 mg subcutaneous injection, 36 month period, statistically significant results"}}
{"sample_id": "AMGN_0001193125-08-018440_2008-02-04", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2008-02-04", "acc_no": "0001193125-08-018440", "sic": "2836", "text_length": 6063}, "classification": {"clinical": "no", "summary": "Amgen and Takeda enter into multiple agreements for product development and commercialization, including a Japan License Agreement and a Global License Agreement for motesanib diphosphate.", "event_type": "Initiation", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "2008-02-03", "evidence_spans": "Item 1.01, Exhibit 99.1, press release dated February 3, 2008"}}
{"sample_id": "AMGN_0001193125-07-169786_2007-08-03", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2007-08-03", "acc_no": "0001193125-07-169786", "sic": "2836", "text_length": 3172}, "classification": {"clinical": "no", "summary": "Announcement of Dennis M. Fenton's retirement and resignation, and appointment of Fabrizio Bonanni as Executive Vice President, Operations.", "event_type": "Modification", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "2007-08-01", "evidence_spans": "Exhibit 99.1, Press release dated August 1, 2007"}}
{"sample_id": "AMGN_0001193125-06-086852_2006-04-24", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2006-04-24", "acc_no": "0001193125-06-086852", "sic": "2836", "text_length": 13445}, "classification": {"clinical": "no", "summary": "Amgen announces Q1 2006 financial results, discusses Phase 3 osteoporosis trial expected to complete in 2008.", "event_type": "Results", "phase": "3", "outcome": "unknown", "confidence": "none", "press_release_date": "2006-04-18", "evidence_spans": "Item 2.02, April 18, 2006, pivotal phase 3 clinical trial, expected to complete in 2008"}}
{"sample_id": "AMGN_0001193125-05-082967_2005-04-25", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2005-04-25", "acc_no": "0001193125-05-082967", "sic": "2836", "text_length": 3223}, "classification": {"clinical": "no", "summary": "Amendment to Promotion Agreement between Amgen, Immunex, and Wyeth regarding cost-sharing for medical affairs functions.", "event_type": "Modification", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "unknown", "evidence_spans": "Item 1.01. Entry into a Material Definitive Agreement."}}
{"sample_id": "AMGN_0000950168-02-001902_2002-07-16", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 318154, "ticker": "AMGN", "company": "AMGEN INC", "form": "8-K", "filing_date": "2002-07-16", "acc_no": "0000950168-02-001902", "sic": "2836", "text_length": 59041}, "classification": {"clinical": "no", "summary": "Amgen acquired Immunex, gaining rights to Enbrel and other products. Enbrel faces supply constraints and competition.", "event_type": "Acquisition", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "2002-07-16", "evidence_spans": "Item 2. Acquisition or Disposition of Assets, On July 15, 2002, Amgen Inc. (Amgen) announced the closing of its acquisition of Immunex Corporation (Immunex)"}}
{"sample_id": "GILD_0000950103-24-002027_2024-02-12", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 882095, "ticker": "GILD", "company": "GILEAD SCIENCES, INC.", "form": "8-K", "filing_date": "2024-02-12", "acc_no": "0000950103-24-002027", "sic": "2836", "text_length": 16852}, "classification": {"clinical": "no", "summary": "Gilead Sciences entered into a Merger Agreement with CymaBay Therapeutics to acquire all outstanding shares for $32.50 per share.", "event_type": "Initiation", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "2024-02-12", "evidence_spans": "Item 1.01, Item 8.01, Item 9.01"}}
{"sample_id": "GILD_0001104659-22-030888_2022-03-07", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 882095, "ticker": "GILD", "company": "GILEAD SCIENCES, INC.", "form": "8-K", "filing_date": "2022-03-07", "acc_no": "0001104659-22-030888", "sic": "2836", "text_length": 3950}, "classification": {"clinical": "yes", "summary": "Gilead announces Phase 3 TROPiCS-02 study results for Trodelvy in HR+/HER2- metastatic breast cancer.", "event_type": "Results", "phase": "3", "outcome": "unknown", "confidence": "none", "press_release_date": "2022-03-07", "evidence_spans": "Press Release, issued by Gilead Sciences, Inc. on March 7, 2022, Phase 3 TROPiCS-02 study"}}
{"sample_id": "GILD_0000950103-20-017822_2020-09-14", "source_file": "filings_sample.json", "guided_generation": true, "api_base": "https://app-clinical-classifier.cloud.aau.dk/v1", "model": "qwen25-72b-instruct-awq", "metadata": {"cik": 882095, "ticker": "GILD", "company": "GILEAD SCIENCES, INC.", "form": "8-K", "filing_date": "2020-09-14", "acc_no": "0000950103-20-017822", "sic": "2836", "text_length": 17622}, "classification": {"clinical": "no", "summary": "Gilead Sciences announces a merger with Immunomedics, involving a tender offer for all Immunomedics shares at $88 per share.", "event_type": "Initiation", "phase": "unknown", "outcome": "unknown", "confidence": "none", "press_release_date": "2020-09-13", "evidence_spans": "Item 1.01. Entry into a Material Definitive Agreement, Item 8.01. Other Events"}}
